EMD Millipore and Proteomics International are joining forces to validate biomarkers related to diabetic nephropathy. The aim is to be able to use the biomarkers to monitor the progression and prognosis of kidney disease in patients with diabetes.
Proteomics International will assess its 13 newly identified putative protein biomarkers by using EMD Millipore’s multiplex immunoassays. These biomarkers include proteins involved in metabolism, inflammation, and oxidative stress. Proteomics International will also utilize its sample repository of relevant clinical specimens to assess additional biomarkers developed by EMD Millipore.
Currently, diabetic nephropathy is screened using the microalbumin test, which looks for a single biomarker in urine. Several of the newly identified biomarkers show promise in enhancing the current screening methods by identifying a signature of biomarkers in blood that can better represent disease prediction and progression, according to EMD and Proteomics International.
“We expect this opportunity will enable EMD Millipore to expand our substantial portfolio of ELISA and Milliplex® multiplexed-bead based assays for diabetes and metabolic disease biomarkers,” notes Jehangir Mistry, Ph.D., director of R&D at EMD Millipore. “In addition to their biomarkers, Proteomics International brings access to large, highly stratified patient cohorts in Australia to validate assay performance. This will help us determine the clinical utility of the biomarkers for development of potential diagnostic tests for diabetic nephropathy.”
|
EMD Millipore and Proteomics International are joining forces to validate biomarkers related to diabetic nephropathy. The aim is to be able to use the biomarkers to monitor the progression and prognosis of kidney disease in patients with diabetes.
|
Proteomics International will assess its 13 newly identified putative protein biomarkers by using EMD Millipore’s multiplex immunoassays. These biomarkers include proteins involved in metabolism, inflammation, and oxidative stress. Proteomics International will also utilize its sample repository of relevant clinical specimens to assess additional biomarkers developed by EMD Millipore.
|
Currently, diabetic nephropathy is screened using the microalbumin test, which looks for a single biomarker in urine. Several of the newly identified biomarkers show promise in enhancing the current screening methods by identifying a signature of biomarkers in blood that can better represent disease prediction and progression, according to EMD and Proteomics International.
“We expect this opportunity will enable EMD Millipore to expand our substantial portfolio of ELISA and Milliplex® multiplexed-bead based assays for diabetes and metabolic disease biomarkers,” notes Jehangir Mistry, Ph.D., director of R&D at EMD Millipore. “In addition to their biomarkers, Proteomics International brings access to large, highly stratified patient cohorts in Australia to validate assay performance. This will help us determine the clinical utility of the biomarkers for development of potential diagnostic tests for diabetic nephropathy.”
|
“We chose to partner with EMD Millipore because of their extensive portfolio of developed protein biomarkers and custom assay development expertise,” said Richard Lipscombe, Ph.D., Managing Director of Proteomics International. “We are very excited to be working with EMD Millipore to progress our initial discovery of these biomarkers that could improve diagnosis and health outcomes on such a large scale.”